Engineered immune cells take on advanced lung cancer in early trial
NCT ID NCT02592577
First seen Jan 08, 2026 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This early-phase trial tested a new treatment for people with advanced non-small cell lung cancer that had grown or returned after standard therapy. Researchers took participants' own immune cells, genetically modified them in a lab to target cancer cells, and infused them back after chemotherapy. The main goals were to check safety and find the best dose. 28 adults took part, and the study is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Duke University Medical Center, Duke Cancer Institute
Durham, North Carolina, 27710, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
H. Lee Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Hospital Universitario 12 Octubre Avda. de Córdoba s/n
Madrid, Madrid, 28041, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, Madrid, 28040, Spain
-
Indiana University Simon Cancer Center
Indianapolis, Indiana, 46033, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Ohio State University Wexner Medical Center
Columbus, Ohio, 43210, United States
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G1X6, Canada
-
Stanford Cancer Center
Palo Alto, California, 94304, United States
-
Tennessee Oncology- Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University College Hospital Macmillan Cancer Centre
London, WC1E 6AG, United Kingdom
-
University of Maryland, Greenebaum Cancer Center
Baltimore, Maryland, 21157, United States
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
-
Washington University, School of Medicine
St Louis, Missouri, 63110, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.